drugset / Trial / NCT01390402
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML. The safety of this treatment will also be studied.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |
| Background | Busulfan | Small molecule | 130 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 40 mg/m2 | Intravenous |
| Background | Methotrexate | Small molecule | 5 mg/m2 | Intravenous |
| Background | Tacrolimus | Small molecule | 0.015 mg/kg | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 500000 iu | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |